First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors

Garralda, E. (Elena); Geva, R. (Ravit); Ben-Ami, E. (Eytan); Maurice-Dror, C. (Corinne); Calvo, E. (Emiliano); Lorusso, P. (Patricia); Türec, Ö. (Özlem); Niewood, M. (Michelle); Sahin, U. (Ugur); Jure-Kunkel, M. (María); Forssmann, U. (Ulf); Ahmadi, T. (Tahamtan); Melero, I. (Ignacio)

Palabras clave :

Cancer immunotherapies
Monotherapy
T cells

Fecha de publicación :

2020

Editorial :

BMJ

ISSN :

2051-1426

Nota:

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Cita:

Garralda, E. (Elena); Geva, R. (Ravit); Ben-Ami, E. (Eytan); et al. "First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors". Journal for immunotherapy of cancer. 8 (Suppl 3), 2020, A1 - A559

Resumen

Agonistic 4-1BB monoclonal antibodies were preclinically validated as promising cancer immunotherapies, both as monotherapy and as potentiators of the activity of PD-(L) 1–blocking agents. However, toxicity and a narrow therapeutic window have hampered their clinical development. DuoBodyPD-L1×4-1BB, a first-in-class, bispecific, next-generation checkpoint immunotherapy, was designed to overcome these limitations by activating T cells through conditional 4-1BB costimulation, while simultaneously blocking the PD-L1 axis. We present preliminary data from the ongoing, first-in-human, open-label, phase I/IIa trial of DuoBody-PD-L1×4-1BB in advanced solid tumors (NCT03917381).

URI :

https://hdl.handle.net/10171/66226

DOI:

10.1136/jitc-2020-SITC2020.0412

Aparece en las colecciones:

DA - CIMA - Inmunología e Inmunoterapia - Inmunología terapia génica - Artículos de revista

Ficheros en este ítem: